Overview

This trial is active, not recruiting.

Condition chorioretinitis
Treatments pyrimethamine-sulfadiazine + prednisolone, clindamycin+dexamethasone
Phase phase 3
Sponsor Shahid Beheshti Medical University
Start date July 2005
End date August 2008
Trial identifier NCT00372294, 8415

Summary

Toxoplasmosis, an intra cellular parasite, is a very important cause of chorioretinitis. The goal of treatment is arresting multiplication of the parasite in its inflammatory active phase. In this study the investigators try to compare the efficacy of the classic regimen (Pyrimethamine-Sulfadiazine + Prednisolon) with intravitreal Clindamycin & Dexamethasone.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking single blind (subject)
Primary purpose treatment
Arm
(Active Comparator)
Classic regimen (Pyrimethamine-Sulfadiazine + Prednisolon)
pyrimethamine-sulfadiazine + prednisolone
Administration of pyrimethamine-sulfadiazine + prednisolone
(Active Comparator)
Intravitreal Clindamycin & Dexamethasone
clindamycin+dexamethasone
Intravitreal injection of Clindamycin+Dexamethasone

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: - Patients with Toxoplasmic chorioretinitis - Location of the lesion within zone I of the retina or a lesion greater than 2DD with 3+-4+ vitreous inflammation in zone II or III - No allergic history to the used drugs - No any other diseases Exclusion Criteria: - Any allergic reaction to the used medications - One eyed patients - Partially treated patients

Additional Information

Principal investigator Masoud Soheilian, MD
Trial information was received from ClinicalTrials.gov and was last updated in July 2008.
Information provided to ClinicalTrials.gov by Shahid Beheshti Medical University.